The evolving role of gemcitabine and pemetrexed (Alimta®) in the management of patients with malignant mesothelioma

Clinical Lung Cancer

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Green, Mark R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antifolate; Carboplatin; Cisplatin; Multitargeted antifolate; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DIHYDROFOLATE REDUCTASE; DNA TOPOISOMERASE INHIBITOR; EPIRUBICIN; FOLIC ACID; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLACEBO; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG POTENTIATION; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INOPERABLE CANCER; MALIGNANT MESOTHELIOMA; MEDICAL SOCIETY; NONHUMAN; PLEURODESIS; PNEUMONIA; SURVIVAL TIME;

EID: 0036241256     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/clc.2002.s.005     Document Type: Article

References (24)

1. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
2. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
3. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
4. Chemotherapy in malignant pleural mesothelioma. A review
5. Gemcitabine for malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B (CALGB 9530)
6. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
7. Gemcitabine (Gemzar®) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
8. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma
9. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
10. Multicentre phase II study of cisplatin (C) and gemcitabine (G) in malignant mesothelioma (MM)
11. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
12. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: A phase II study of the GSTPV
13. Phase II study: Gemcitabine plus epirubicin in malignant pleural mesothelioma. An AIPO Chest Oncology Study Group trial
14. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents
15. MTA (LY231514) in combination treatment regiments using human tumor xenografts and the EMT-6 murine mammary carcinoma
16. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts
17. Overview of phase I trials of multitargeted antifolate (MTA, LY231514)
18. Overview of phase II trials of MTA in solid tumors
19. Activity of the multitargeted antifolate MTA (LY231514) in advanced non-small lung cell lung cancer (NSCLC)
20. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite
21. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors
22. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
23. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
24. Phase II study of Alimta (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma